Back to Search Start Over

Prescribed exercise to Reduce Recidivism After Weight Loss-Pilot (PREVAIL-P): Design, methods and rationale

Authors :
Joseph A. Houmard
Gabriel S. Dubis
Corby K. Martin
Charles J. Tanner
Robert A. Carels
Damon L. Swift
Laura E. Matarese
Savanna G. Barefoot
Walter J. Pories
Angela Clark
Briceida G. Osborne
Taylor T. Brown
Marie C Clunan
Joshua E. McGee
Nicole R. Gniewek
Colleen Bucher
Patricia Brophy
Anna C Huff
Robbie A. Beyl
Source :
Contemporary Clinical Trials Communications, Vol 21, Iss, Pp 100717-(2021), Contemporary Clinical Trials Communications
Publication Year :
2021
Publisher :
Elsevier, 2021.

Abstract

Clinically significant weight loss is associated with health benefits for overweight and obese adults. Participation in adequate amounts of physical activity is critical for weight maintenance. However, the recommended amount of physical activity needed to promote weight maintenance is based primarily on retrospective studies that quantified physical activity levels through questionnaires which tend to overestimate physical activity levels. In addition, the present literature has provided little data on the impact of these physical activity levels on cardiovascular and diabetes risk factors, which may have equal or more clinical importance than weight changes. The Prescribed Exercise to Reduce Recidivism After Weight Loss-Pilot (PREVAIL-P) study will evaluate the effect of aerobic exercise training amount on weight maintenance following clinically significant weight loss in overweight and obese adults (BMI 25–40 kg/m2) age 30–65 years. Participants (N = 39) will complete a 10-week OPTIFAST® weight loss program with supervised aerobic exercise training. Individuals who achieve ≥7% weight loss from baseline will be subsequently randomized to levels of aerobic training consistent with physical activity recommendations (PA-REC) or weight maintenance recommendations (WM-REC) for 18 additional weeks. The primary outcome of the PREVAIL-P study will be change in weight from the completion of OPTIFAST® program to the end of the study. Notable secondary measures include changes in clinically relevant cardiometabolic risk factors between study groups (e.g. blood lipids concentrations, oral glucose tolerance, arterial stiffness). This pilot study will be used to estimate the effect sizes needed for a randomized controlled trial on this topic.

Details

Language :
English
ISSN :
24518654
Volume :
21
Database :
OpenAIRE
Journal :
Contemporary Clinical Trials Communications
Accession number :
edsair.doi.dedup.....f4d90019fbd45714f3bc0ace2964b5b2